Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial
Adjuvant radiotherapy reduces the risk of biochemical progression in prostate cancer patients after radical prostatectomy. We aimed to compare adjuvant versus early salvage radiotherapy after radical prostatectomy, combined with short-term hormonal therapy, in terms of oncological outcomes and toler...
Saved in:
| Published in | The lancet oncology Vol. 21; no. 10; pp. 1341 - 1352 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Ltd
01.10.2020
Elsevier Limited Elsevier |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1470-2045 1474-5488 1474-5488 |
| DOI | 10.1016/S1470-2045(20)30454-X |
Cover
| Abstract | Adjuvant radiotherapy reduces the risk of biochemical progression in prostate cancer patients after radical prostatectomy. We aimed to compare adjuvant versus early salvage radiotherapy after radical prostatectomy, combined with short-term hormonal therapy, in terms of oncological outcomes and tolerance.
GETUG-AFU 17 was a randomised, open-label, multicentre, phase 3 trial done at 46 French hospitals. Men aged at least 18 years who had an Eastern Cooperative Oncology Group performance status of 1 or less, localised adenocarcinoma of the prostate treated with radical prostatectomy, who had pathologically-staged pT3a, pT3b, or pT4a (with bladder neck invasion), pNx (without pelvic lymph nodes dissection), or pN0 (with negative lymph nodes dissection) disease, and who had positive surgical margins were eligible for inclusion in the study. Eligible patients were randomly assigned (1:1) to either immediate adjuvant radiotherapy or delayed salvage radiotherapy at the time of biochemical relapse. Random assignment, by minimisation, was done using web-based software and stratified by Gleason score, pT stage, and centre. All patients received 6 months of triptorelin (intramuscular injection every 3 months). The primary endpoint was event-free survival. Efficacy and safety analyses were done on the intention-to-treat population. The trial is registered with ClinicalTrials.gov, NCT00667069.
Between March 7, 2008, and June 23, 2016, 424 patients were enrolled. We planned to enrol 718 patients, with 359 in each study group. However, on May 20, 2016, the independent data monitoring committee recommended early termination of enrolment because of unexpectedly low event rates. At database lock on Dec 19, 2019, the overall median follow-up time from random assignment was 75 months (IQR 50–100), 74 months (47–100) in the adjuvant radiotherapy group and 78 months (52–101) in the salvage radiotherapy group. In the salvage radiotherapy group, 115 (54%) of 212 patients initiated study treatment after biochemical relapse. 205 (97%) of 212 patients started treatment in the adjuvant group. 5-year event-free survival was 92% (95% CI 86–95) in the adjuvant radiotherapy group and 90% (85–94) in the salvage radiotherapy group (HR 0·81, 95% CI 0·48–1·36; log-rank p=0·42). Acute grade 3 or worse toxic effects occurred in six (3%) of 212 patients in the adjuvant radiotherapy group and in four (2%) of 212 patients in the salvage radiotherapy group. Late grade 2 or worse genitourinary toxicities were reported in 125 (59%) of 212 patients in the adjuvant radiotherapy group and 46 (22%) of 212 patients in the salvage radiotherapy group. Late genitourinary adverse events of grade 2 or worse were reported in 58 (27%) of 212 patients in the adjuvant radiotherapy group versus 14 (7%) of 212 patients in the salvage radiotherapy group (p<0·0001). Late erectile dysfunction was grade 2 or worse in 60 (28%) of 212 in the adjuvant radiotherapy group and 17 (8%) of 212 in the salvage radiotherapy group (p<0·0001).
Although our analysis lacked statistical power, we found no benefit for event-free survival in patients assigned to adjuvant radiotherapy compared with patients assigned to salvage radiotherapy. Adjuvant radiotherapy increased the risk of genitourinary toxicity and erectile dysfunction. A policy of early salvage radiotherapy could spare men from overtreatment with radiotherapy and the associated adverse events.
French Health Ministry and Ipsen. |
|---|---|
| AbstractList | Background: Adjuvant radiotherapy reduces the risk of biochemical progression in prostate cancer patients after radical prostatectomy. We aimed to compare adjuvant versus early salvage radiotherapy after radical prostatectomy, combined with short-term hormonal therapy, in terms of oncological outcomes and tolerance.Methods: GETUG-AFU 17 was a randomised, open-label, multicentre, phase 3 trial done at 46 French hospitals. Men aged at least 18 years who had an Eastern Cooperative Oncology Group performance status of 1 or less, localised adenocarcinoma of the prostate treated with radical prostatectomy, who had pathologically-staged pT3a, pT3b, or pT4a (with bladder neck invasion), pNx (without pelvic lymph nodes dissection), or pN0 (with negative lymph nodes dissection) disease, and who had positive surgical margins were eligible for inclusion in the study. Eligible patients were randomly assigned (1:1) to either immediate adjuvant radiotherapy or delayed salvage radiotherapy at the time of biochemical relapse. Random assignment, by minimisation, was done using web-based software and stratified by Gleason score, pT stage, and centre. All patients received 6 months of triptorelin (intramuscular injection every 3 months). The primary endpoint was event-free survival. Efficacy and safety analyses were done on the intention-to-treat population. The trial is registered with ClinicalTrials.gov, NCT00667069.Findings: Between March 7, 2008, and June 23, 2016, 424 patients were enrolled. We planned to enrol 718 patients, with 359 in each study group. However, on May 20, 2016, the independent data monitoring committee recommended early termination of enrolment because of unexpectedly low event rates. At database lock on Dec 19, 2019, the overall median follow-up time from random assignment was 75 months (IQR 50-100), 74 months (47-100) in the adjuvant radiotherapy group and 78 months (52-101) in the salvage radiotherapy group. In the salvage radiotherapy group, 115 (54%) of 212 patients initiated study treatment after biochemical relapse. 205 (97%) of 212 patients started treatment in the adjuvant group. 5-year event-free survival was 92% (95% CI 86-95) in the adjuvant radiotherapy group and 90% (85-94) in the salvage radiotherapy group (HR 0·81, 95% CI 0·48-1·36; log-rank p=0·42). Acute grade 3 or worse toxic effects occurred in six (3%) of 212 patients in the adjuvant radiotherapy group and in four (2%) of 212 patients in the salvage radiotherapy group. Late grade 2 or worse genitourinary toxicities were reported in 125 (59%) of 212 patients in the adjuvant radiotherapy group and 46 (22%) of 212 patients in the salvage radiotherapy group. Late genitourinary adverse events of grade 2 or worse were reported in 58 (27%) of 212 patients in the adjuvant radiotherapy group versus 14 (7%) of 212 patients in the salvage radiotherapy group (p<0·0001). Late erectile dysfunction was grade 2 or worse in 60 (28%) of 212 in the adjuvant radiotherapy group and 17 (8%) of 212 in the salvage radiotherapy group (p<0·0001).Interpretation: Although our analysis lacked statistical power, we found no benefit for event-free survival in patients assigned to adjuvant radiotherapy compared with patients assigned to salvage radiotherapy. Adjuvant radiotherapy increased the risk of genitourinary toxicity and erectile dysfunction. A policy of early salvage radiotherapy could spare men from overtreatment with radiotherapy and the associated adverse events.Funding: French Health Ministry and Ipsen. Summary Background Adjuvant radiotherapy reduces the risk of biochemical progression in prostate cancer patients after radical prostatectomy. We aimed to compare adjuvant versus early salvage radiotherapy after radical prostatectomy, combined with short-term hormonal therapy, in terms of oncological outcomes and tolerance. Methods GETUG-AFU 17 was a randomised, open-label, multicentre, phase 3 trial done at 46 French hospitals. Men aged at least 18 years who had an Eastern Cooperative Oncology Group performance status of 1 or less, localised adenocarcinoma of the prostate treated with radical prostatectomy, who had pathologically-staged pT3a, pT3b, or pT4a (with bladder neck invasion), pNx (without pelvic lymph nodes dissection), or pN0 (with negative lymph nodes dissection) disease, and who had positive surgical margins were eligible for inclusion in the study. Eligible patients were randomly assigned (1:1) to either immediate adjuvant radiotherapy or delayed salvage radiotherapy at the time of biochemical relapse. Random assignment, by minimisation, was done using web-based software and stratified by Gleason score, pT stage, and centre. All patients received 6 months of triptorelin (intramuscular injection every 3 months). The primary endpoint was event-free survival. Efficacy and safety analyses were done on the intention-to-treat population. The trial is registered with ClinicalTrials.gov, NCT00667069. Findings Between March 7, 2008, and June 23, 2016, 424 patients were enrolled. We planned to enrol 718 patients, with 359 in each study group. However, on May 20, 2016, the independent data monitoring committee recommended early termination of enrolment because of unexpectedly low event rates. At database lock on Dec 19, 2019, the overall median follow-up time from random assignment was 75 months (IQR 50–100), 74 months (47–100) in the adjuvant radiotherapy group and 78 months (52–101) in the salvage radiotherapy group. In the salvage radiotherapy group, 115 (54%) of 212 patients initiated study treatment after biochemical relapse. 205 (97%) of 212 patients started treatment in the adjuvant group. 5-year event-free survival was 92% (95% CI 86–95) in the adjuvant radiotherapy group and 90% (85–94) in the salvage radiotherapy group (HR 0·81, 95% CI 0·48–1·36; log-rank p=0·42). Acute grade 3 or worse toxic effects occurred in six (3%) of 212 patients in the adjuvant radiotherapy group and in four (2%) of 212 patients in the salvage radiotherapy group. Late grade 2 or worse genitourinary toxicities were reported in 125 (59%) of 212 patients in the adjuvant radiotherapy group and 46 (22%) of 212 patients in the salvage radiotherapy group. Late genitourinary adverse events of grade 2 or worse were reported in 58 (27%) of 212 patients in the adjuvant radiotherapy group versus 14 (7%) of 212 patients in the salvage radiotherapy group (p<0·0001). Late erectile dysfunction was grade 2 or worse in 60 (28%) of 212 in the adjuvant radiotherapy group and 17 (8%) of 212 in the salvage radiotherapy group (p<0·0001). Interpretation Although our analysis lacked statistical power, we found no benefit for event-free survival in patients assigned to adjuvant radiotherapy compared with patients assigned to salvage radiotherapy. Adjuvant radiotherapy increased the risk of genitourinary toxicity and erectile dysfunction. A policy of early salvage radiotherapy could spare men from overtreatment with radiotherapy and the associated adverse events. Funding French Health Ministry and Ipsen. Adjuvant radiotherapy reduces the risk of biochemical progression in prostate cancer patients after radical prostatectomy. We aimed to compare adjuvant versus early salvage radiotherapy after radical prostatectomy, combined with short-term hormonal therapy, in terms of oncological outcomes and tolerance. GETUG-AFU 17 was a randomised, open-label, multicentre, phase 3 trial done at 46 French hospitals. Men aged at least 18 years who had an Eastern Cooperative Oncology Group performance status of 1 or less, localised adenocarcinoma of the prostate treated with radical prostatectomy, who had pathologically-staged pT3a, pT3b, or pT4a (with bladder neck invasion), pNx (without pelvic lymph nodes dissection), or pN0 (with negative lymph nodes dissection) disease, and who had positive surgical margins were eligible for inclusion in the study. Eligible patients were randomly assigned (1:1) to either immediate adjuvant radiotherapy or delayed salvage radiotherapy at the time of biochemical relapse. Random assignment, by minimisation, was done using web-based software and stratified by Gleason score, pT stage, and centre. All patients received 6 months of triptorelin (intramuscular injection every 3 months). The primary endpoint was event-free survival. Efficacy and safety analyses were done on the intention-to-treat population. The trial is registered with ClinicalTrials.gov, NCT00667069. Between March 7, 2008, and June 23, 2016, 424 patients were enrolled. We planned to enrol 718 patients, with 359 in each study group. However, on May 20, 2016, the independent data monitoring committee recommended early termination of enrolment because of unexpectedly low event rates. At database lock on Dec 19, 2019, the overall median follow-up time from random assignment was 75 months (IQR 50–100), 74 months (47–100) in the adjuvant radiotherapy group and 78 months (52–101) in the salvage radiotherapy group. In the salvage radiotherapy group, 115 (54%) of 212 patients initiated study treatment after biochemical relapse. 205 (97%) of 212 patients started treatment in the adjuvant group. 5-year event-free survival was 92% (95% CI 86–95) in the adjuvant radiotherapy group and 90% (85–94) in the salvage radiotherapy group (HR 0·81, 95% CI 0·48–1·36; log-rank p=0·42). Acute grade 3 or worse toxic effects occurred in six (3%) of 212 patients in the adjuvant radiotherapy group and in four (2%) of 212 patients in the salvage radiotherapy group. Late grade 2 or worse genitourinary toxicities were reported in 125 (59%) of 212 patients in the adjuvant radiotherapy group and 46 (22%) of 212 patients in the salvage radiotherapy group. Late genitourinary adverse events of grade 2 or worse were reported in 58 (27%) of 212 patients in the adjuvant radiotherapy group versus 14 (7%) of 212 patients in the salvage radiotherapy group (p<0·0001). Late erectile dysfunction was grade 2 or worse in 60 (28%) of 212 in the adjuvant radiotherapy group and 17 (8%) of 212 in the salvage radiotherapy group (p<0·0001). Although our analysis lacked statistical power, we found no benefit for event-free survival in patients assigned to adjuvant radiotherapy compared with patients assigned to salvage radiotherapy. Adjuvant radiotherapy increased the risk of genitourinary toxicity and erectile dysfunction. A policy of early salvage radiotherapy could spare men from overtreatment with radiotherapy and the associated adverse events. French Health Ministry and Ipsen. SummaryBackgroundAdjuvant radiotherapy reduces the risk of biochemical progression in prostate cancer patients after radical prostatectomy. We aimed to compare adjuvant versus early salvage radiotherapy after radical prostatectomy, combined with short-term hormonal therapy, in terms of oncological outcomes and tolerance. MethodsGETUG-AFU 17 was a randomised, open-label, multicentre, phase 3 trial done at 46 French hospitals. Men aged at least 18 years who had an Eastern Cooperative Oncology Group performance status of 1 or less, localised adenocarcinoma of the prostate treated with radical prostatectomy, who had pathologically-staged pT3a, pT3b, or pT4a (with bladder neck invasion), pNx (without pelvic lymph nodes dissection), or pN0 (with negative lymph nodes dissection) disease, and who had positive surgical margins were eligible for inclusion in the study. Eligible patients were randomly assigned (1:1) to either immediate adjuvant radiotherapy or delayed salvage radiotherapy at the time of biochemical relapse. Random assignment, by minimisation, was done using web-based software and stratified by Gleason score, pT stage, and centre. All patients received 6 months of triptorelin (intramuscular injection every 3 months). The primary endpoint was event-free survival. Efficacy and safety analyses were done on the intention-to-treat population. The trial is registered with ClinicalTrials.gov, NCT00667069. FindingsBetween March 7, 2008, and June 23, 2016, 424 patients were enrolled. We planned to enrol 718 patients, with 359 in each study group. However, on May 20, 2016, the independent data monitoring committee recommended early termination of enrolment because of unexpectedly low event rates. At database lock on Dec 19, 2019, the overall median follow-up time from random assignment was 75 months (IQR 50–100), 74 months (47–100) in the adjuvant radiotherapy group and 78 months (52–101) in the salvage radiotherapy group. In the salvage radiotherapy group, 115 (54%) of 212 patients initiated study treatment after biochemical relapse. 205 (97%) of 212 patients started treatment in the adjuvant group. 5-year event-free survival was 92% (95% CI 86–95) in the adjuvant radiotherapy group and 90% (85–94) in the salvage radiotherapy group (HR 0·81, 95% CI 0·48–1·36; log-rank p=0·42). Acute grade 3 or worse toxic effects occurred in six (3%) of 212 patients in the adjuvant radiotherapy group and in four (2%) of 212 patients in the salvage radiotherapy group. Late grade 2 or worse genitourinary toxicities were reported in 125 (59%) of 212 patients in the adjuvant radiotherapy group and 46 (22%) of 212 patients in the salvage radiotherapy group. Late genitourinary adverse events of grade 2 or worse were reported in 58 (27%) of 212 patients in the adjuvant radiotherapy group versus 14 (7%) of 212 patients in the salvage radiotherapy group (p<0·0001). Late erectile dysfunction was grade 2 or worse in 60 (28%) of 212 in the adjuvant radiotherapy group and 17 (8%) of 212 in the salvage radiotherapy group (p<0·0001). InterpretationAlthough our analysis lacked statistical power, we found no benefit for event-free survival in patients assigned to adjuvant radiotherapy compared with patients assigned to salvage radiotherapy. Adjuvant radiotherapy increased the risk of genitourinary toxicity and erectile dysfunction. A policy of early salvage radiotherapy could spare men from overtreatment with radiotherapy and the associated adverse events. FundingFrench Health Ministry and Ipsen. Adjuvant radiotherapy reduces the risk of biochemical progression in prostate cancer patients after radical prostatectomy. We aimed to compare adjuvant versus early salvage radiotherapy after radical prostatectomy, combined with short-term hormonal therapy, in terms of oncological outcomes and tolerance.BACKGROUNDAdjuvant radiotherapy reduces the risk of biochemical progression in prostate cancer patients after radical prostatectomy. We aimed to compare adjuvant versus early salvage radiotherapy after radical prostatectomy, combined with short-term hormonal therapy, in terms of oncological outcomes and tolerance.GETUG-AFU 17 was a randomised, open-label, multicentre, phase 3 trial done at 46 French hospitals. Men aged at least 18 years who had an Eastern Cooperative Oncology Group performance status of 1 or less, localised adenocarcinoma of the prostate treated with radical prostatectomy, who had pathologically-staged pT3a, pT3b, or pT4a (with bladder neck invasion), pNx (without pelvic lymph nodes dissection), or pN0 (with negative lymph nodes dissection) disease, and who had positive surgical margins were eligible for inclusion in the study. Eligible patients were randomly assigned (1:1) to either immediate adjuvant radiotherapy or delayed salvage radiotherapy at the time of biochemical relapse. Random assignment, by minimisation, was done using web-based software and stratified by Gleason score, pT stage, and centre. All patients received 6 months of triptorelin (intramuscular injection every 3 months). The primary endpoint was event-free survival. Efficacy and safety analyses were done on the intention-to-treat population. The trial is registered with ClinicalTrials.gov, NCT00667069.METHODSGETUG-AFU 17 was a randomised, open-label, multicentre, phase 3 trial done at 46 French hospitals. Men aged at least 18 years who had an Eastern Cooperative Oncology Group performance status of 1 or less, localised adenocarcinoma of the prostate treated with radical prostatectomy, who had pathologically-staged pT3a, pT3b, or pT4a (with bladder neck invasion), pNx (without pelvic lymph nodes dissection), or pN0 (with negative lymph nodes dissection) disease, and who had positive surgical margins were eligible for inclusion in the study. Eligible patients were randomly assigned (1:1) to either immediate adjuvant radiotherapy or delayed salvage radiotherapy at the time of biochemical relapse. Random assignment, by minimisation, was done using web-based software and stratified by Gleason score, pT stage, and centre. All patients received 6 months of triptorelin (intramuscular injection every 3 months). The primary endpoint was event-free survival. Efficacy and safety analyses were done on the intention-to-treat population. The trial is registered with ClinicalTrials.gov, NCT00667069.Between March 7, 2008, and June 23, 2016, 424 patients were enrolled. We planned to enrol 718 patients, with 359 in each study group. However, on May 20, 2016, the independent data monitoring committee recommended early termination of enrolment because of unexpectedly low event rates. At database lock on Dec 19, 2019, the overall median follow-up time from random assignment was 75 months (IQR 50-100), 74 months (47-100) in the adjuvant radiotherapy group and 78 months (52-101) in the salvage radiotherapy group. In the salvage radiotherapy group, 115 (54%) of 212 patients initiated study treatment after biochemical relapse. 205 (97%) of 212 patients started treatment in the adjuvant group. 5-year event-free survival was 92% (95% CI 86-95) in the adjuvant radiotherapy group and 90% (85-94) in the salvage radiotherapy group (HR 0·81, 95% CI 0·48-1·36; log-rank p=0·42). Acute grade 3 or worse toxic effects occurred in six (3%) of 212 patients in the adjuvant radiotherapy group and in four (2%) of 212 patients in the salvage radiotherapy group. Late grade 2 or worse genitourinary toxicities were reported in 125 (59%) of 212 patients in the adjuvant radiotherapy group and 46 (22%) of 212 patients in the salvage radiotherapy group. Late genitourinary adverse events of grade 2 or worse were reported in 58 (27%) of 212 patients in the adjuvant radiotherapy group versus 14 (7%) of 212 patients in the salvage radiotherapy group (p<0·0001). Late erectile dysfunction was grade 2 or worse in 60 (28%) of 212 in the adjuvant radiotherapy group and 17 (8%) of 212 in the salvage radiotherapy group (p<0·0001).FINDINGSBetween March 7, 2008, and June 23, 2016, 424 patients were enrolled. We planned to enrol 718 patients, with 359 in each study group. However, on May 20, 2016, the independent data monitoring committee recommended early termination of enrolment because of unexpectedly low event rates. At database lock on Dec 19, 2019, the overall median follow-up time from random assignment was 75 months (IQR 50-100), 74 months (47-100) in the adjuvant radiotherapy group and 78 months (52-101) in the salvage radiotherapy group. In the salvage radiotherapy group, 115 (54%) of 212 patients initiated study treatment after biochemical relapse. 205 (97%) of 212 patients started treatment in the adjuvant group. 5-year event-free survival was 92% (95% CI 86-95) in the adjuvant radiotherapy group and 90% (85-94) in the salvage radiotherapy group (HR 0·81, 95% CI 0·48-1·36; log-rank p=0·42). Acute grade 3 or worse toxic effects occurred in six (3%) of 212 patients in the adjuvant radiotherapy group and in four (2%) of 212 patients in the salvage radiotherapy group. Late grade 2 or worse genitourinary toxicities were reported in 125 (59%) of 212 patients in the adjuvant radiotherapy group and 46 (22%) of 212 patients in the salvage radiotherapy group. Late genitourinary adverse events of grade 2 or worse were reported in 58 (27%) of 212 patients in the adjuvant radiotherapy group versus 14 (7%) of 212 patients in the salvage radiotherapy group (p<0·0001). Late erectile dysfunction was grade 2 or worse in 60 (28%) of 212 in the adjuvant radiotherapy group and 17 (8%) of 212 in the salvage radiotherapy group (p<0·0001).Although our analysis lacked statistical power, we found no benefit for event-free survival in patients assigned to adjuvant radiotherapy compared with patients assigned to salvage radiotherapy. Adjuvant radiotherapy increased the risk of genitourinary toxicity and erectile dysfunction. A policy of early salvage radiotherapy could spare men from overtreatment with radiotherapy and the associated adverse events.INTERPRETATIONAlthough our analysis lacked statistical power, we found no benefit for event-free survival in patients assigned to adjuvant radiotherapy compared with patients assigned to salvage radiotherapy. Adjuvant radiotherapy increased the risk of genitourinary toxicity and erectile dysfunction. A policy of early salvage radiotherapy could spare men from overtreatment with radiotherapy and the associated adverse events.French Health Ministry and Ipsen.FUNDINGFrench Health Ministry and Ipsen. |
| Author | Magné, Nicolas Richaud, Pierre Benyoucef, Ahmed Baumann, Pierre Azria, David Belkacemi, Yazid Sargos, Paul Silva, Marlon Soulié, Michel Chabaud, Sylvie Brihoum, Meryem Pasquier, David Bergerot, Philippe Supiot, Stéphane Latorzeff, Igor Gilliot, Olivier Graff-Cailleaud, Pierre Abdiche, Menouar Samir |
| Author_xml | – sequence: 1 givenname: Paul surname: Sargos fullname: Sargos, Paul email: p.sargos@bordeaux.unicancer.fr organization: Institut Bergonié, Bordeaux, France – sequence: 2 givenname: Sylvie surname: Chabaud fullname: Chabaud, Sylvie organization: Centre Léon Bérard, Lyon, France – sequence: 3 givenname: Igor surname: Latorzeff fullname: Latorzeff, Igor organization: Clinique Pasteur, Toulouse, France – sequence: 4 givenname: Nicolas surname: Magné fullname: Magné, Nicolas organization: Institut de Cancérologie de la Loire, Saint-Priest-en-Jarèz, France – sequence: 5 givenname: Ahmed surname: Benyoucef fullname: Benyoucef, Ahmed organization: Centre Henri Becquerel, Rouen, France – sequence: 6 givenname: Stéphane surname: Supiot fullname: Supiot, Stéphane organization: Institut de Cancérologie de l'Ouest, Site René Gauducheau, Saint-Herblain, France – sequence: 7 givenname: David surname: Pasquier fullname: Pasquier, David organization: Centre Oscar Lambret and Lille University, Lille, France – sequence: 8 givenname: Menouar Samir surname: Abdiche fullname: Abdiche, Menouar Samir organization: Centre Hospitalier Robert Boulin, Libourne, France – sequence: 9 givenname: Olivier surname: Gilliot fullname: Gilliot, Olivier organization: Clinique Marzet, Pau, France – sequence: 10 givenname: Pierre surname: Graff-Cailleaud fullname: Graff-Cailleaud, Pierre organization: Institut Claudius Regaud, Toulouse, France – sequence: 11 givenname: Marlon surname: Silva fullname: Silva, Marlon organization: Centre François Baclesse, Caen, France – sequence: 12 givenname: Philippe surname: Bergerot fullname: Bergerot, Philippe organization: Clinique Mutualiste de l'Estuaire, Cité Sanitaire, Saint-Nazaire, France – sequence: 13 givenname: Pierre surname: Baumann fullname: Baumann, Pierre organization: Centre d'Oncologie de Gentilly, Nancy, France – sequence: 14 givenname: Yazid surname: Belkacemi fullname: Belkacemi, Yazid organization: Hôpitaux Universitaires Henri Mondor, Université Paris Est Créteil, Creteil, France – sequence: 15 givenname: David surname: Azria fullname: Azria, David organization: Institut Régional du Cancer de Montpellier Val d'Aurelle, Montpellier, France – sequence: 16 givenname: Meryem surname: Brihoum fullname: Brihoum, Meryem organization: Unicancer, Paris, France – sequence: 17 givenname: Michel surname: Soulié fullname: Soulié, Michel organization: CHU de Toulouse, Toulouse, France – sequence: 18 givenname: Pierre surname: Richaud fullname: Richaud, Pierre organization: Institut Bergonié, Bordeaux, France |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33002438$$D View this record in MEDLINE/PubMed https://hal.science/hal-03491498$$DView record in HAL |
| BookMark | eNqNkluLEzEUxwdZcS_6EZSALy04msxkbisqZdntCgUf3MK-hdPkdJs6ndQkU-nX9BOZ6WwLFmR9ScI5v_M_OZfz6KQxDUbRa0bfM8ryD98ZL2icUJ4NEjpMw83j-2fRWTDzOONlebJ798hpdO7cklJWMJq9iE7TlNKEp-VZ9Huklu0GGk8sKG38Ai2st2SD1rWOINh6SxzUG3jAv4l1HfxuYayPPdoVgUZZ84ANUbi2egNem4bsYd2QVXD90n5BaiOh1g4VWVvjPHgkEhqJlsA8KO2yBOLgld6stmQwvr6bjuPRzZSwYnhJIHCNMqtO6B1ZL8AhSYm3GuqX0fM51A5fPd4X0fTm-u7qNp58G3-9Gk1imZWpDyeTrCixSGa5SrOsAMyylNOikpWaZ5LSYsZTihmAmmXzeVFCyZHOKhW8ScHSi2jY6y6gFqHmFditMKDF7WgiOhtNecV4VW46dtCzoaqfLTovws8l1jU0aFonEs5LzpI8zQP69ghdmtY2oZKOyqs8p3kVqDePVDtboTrk3082AB97QIY-OotzIbXfTcVb0LVgVHR7JHZ7JLolCYfY7ZG4D9HZUfQ-wVNxX_o4DI3faLTCSY1hukrbMEmhjH5S4fORgqx1023ED9yiO_SCCZcI2ot0GgndKXQCn_4t8B8f-AOTJgoi |
| CitedBy_id | crossref_primary_10_1007_s00432_023_05085_3 crossref_primary_10_3390_cancers16162879 crossref_primary_10_1016_j_canrad_2022_06_005 crossref_primary_10_3390_cancers14030696 crossref_primary_10_1016_j_euros_2022_05_011 crossref_primary_10_3390_ijms241512508 crossref_primary_10_1007_s00259_022_05931_5 crossref_primary_10_3390_cancers13205183 crossref_primary_10_1016_j_euros_2022_05_016 crossref_primary_10_1016_j_ctro_2021_07_003 crossref_primary_10_3389_fonc_2021_781040 crossref_primary_10_1038_s41585_021_00497_7 crossref_primary_10_1016_j_eururo_2020_11_032 crossref_primary_10_1016_j_soi_2025_100137 crossref_primary_10_3390_cancers13174339 crossref_primary_10_3390_cancers14194956 crossref_primary_10_1016_j_urolonc_2023_06_003 crossref_primary_10_1038_s41391_021_00347_y crossref_primary_10_1200_JCO_20_02768 crossref_primary_10_2217_epi_2022_0111 crossref_primary_10_1016_j_euo_2023_06_002 crossref_primary_10_3390_cancers14071688 crossref_primary_10_1016_j_prnil_2022_01_003 crossref_primary_10_1200_JCO_22_00645 crossref_primary_10_1016_j_euros_2024_01_009 crossref_primary_10_1016_j_urolonc_2021_06_008 crossref_primary_10_1097_CU9_0000000000000115 crossref_primary_10_1007_s11547_022_01479_4 crossref_primary_10_1016_j_radonc_2024_110690 crossref_primary_10_1016_j_urolonc_2021_03_020 crossref_primary_10_1002_pros_24860 crossref_primary_10_1007_s11864_023_01164_2 crossref_primary_10_3389_fonc_2022_959436 crossref_primary_10_3390_biomedicines10081911 crossref_primary_10_3390_biomedicines10092256 crossref_primary_10_1200_EDBK_430466 crossref_primary_10_1016_j_urology_2025_01_003 crossref_primary_10_3389_fonc_2024_1334845 crossref_primary_10_1016_j_purol_2022_07_148 crossref_primary_10_1016_j_annonc_2024_03_010 crossref_primary_10_1001_jamanetworkopen_2024_34143 crossref_primary_10_3390_cancers17071055 crossref_primary_10_4103_UCCI_UCCI_3_24 crossref_primary_10_2147_CMAR_S357814 crossref_primary_10_1080_14737140_2021_1878883 crossref_primary_10_1016_S0140_6736_21_01790_6 crossref_primary_10_4103_iju_IJU_559_20 crossref_primary_10_1016_S0140_6736_20_31957_7 crossref_primary_10_1016_j_bulcan_2020_11_002 crossref_primary_10_1016_j_prro_2023_09_007 crossref_primary_10_1016_j_modpat_2023_100147 crossref_primary_10_3238_arztebl_m2021_0026 crossref_primary_10_1055_a_2284_0593 crossref_primary_10_1016_S0140_6736_21_00581_X crossref_primary_10_1097_us9_0000000000000033 crossref_primary_10_1111_1754_9485_13552 crossref_primary_10_17650_1726_9776_2023_19_4_86_96 crossref_primary_10_1142_S1793292023501035 crossref_primary_10_1186_s13014_021_01808_3 crossref_primary_10_1016_j_ctro_2024_100786 crossref_primary_10_1016_j_ijrobp_2023_04_032 crossref_primary_10_1007_s41973_025_00289_1 crossref_primary_10_1159_000536609 crossref_primary_10_1016_j_ijrobp_2021_02_017 crossref_primary_10_1016_j_ctro_2022_06_008 crossref_primary_10_1016_j_eururo_2021_02_013 crossref_primary_10_1007_s11845_023_03356_z crossref_primary_10_1016_j_prnil_2021_05_002 crossref_primary_10_3389_fonc_2021_723536 crossref_primary_10_1186_s40644_024_00752_1 crossref_primary_10_1016_j_prro_2024_12_006 crossref_primary_10_1245_s10434_022_11892_8 crossref_primary_10_3390_cancers15174390 crossref_primary_10_1016_j_clgc_2024_102239 crossref_primary_10_53011_JMRO_2021_02_03 crossref_primary_10_1016_S0140_6736_21_00950_8 crossref_primary_10_3389_fonc_2023_1281432 crossref_primary_10_1016_j_acuro_2021_03_004 crossref_primary_10_1002_pros_24169 crossref_primary_10_1016_j_acuroe_2021_07_007 crossref_primary_10_3390_siuj5020020 crossref_primary_10_21641_los_2022_19_1_216 crossref_primary_10_1016_j_ijrobp_2023_10_009 crossref_primary_10_1111_bju_16484 crossref_primary_10_2478_raon_2021_0017 crossref_primary_10_3390_jcm11164651 crossref_primary_10_3390_cancers14030719 crossref_primary_10_1371_journal_pmed_1003629 crossref_primary_10_1016_j_ijrobp_2022_04_048 crossref_primary_10_1007_s00345_023_04605_7 crossref_primary_10_1016_j_eururo_2021_06_017 crossref_primary_10_1007_s10147_024_02580_6 crossref_primary_10_17650_1726_9776_2023_19_2_66_74 crossref_primary_10_3389_fonc_2020_607923 crossref_primary_10_1016_j_ejca_2022_04_038 crossref_primary_10_1186_s13014_025_02599_7 crossref_primary_10_1200_JCO_20_03714 crossref_primary_10_1016_j_euo_2023_02_013 crossref_primary_10_1016_j_radonc_2023_109544 crossref_primary_10_1259_bjrcr_20210039 crossref_primary_10_1016_j_ijrobp_2022_08_041 crossref_primary_10_1007_s12094_020_02543_z crossref_primary_10_1097_SPC_0000000000000627 crossref_primary_10_1016_j_euo_2024_04_019 crossref_primary_10_1001_jamanetworkopen_2024_40747 crossref_primary_10_1007_s00120_021_01501_z crossref_primary_10_1016_j_canrad_2021_07_005 crossref_primary_10_1016_j_purol_2022_01_007 crossref_primary_10_4274_jus_galenos_2021_2021_0098 crossref_primary_10_1016_j_clon_2022_06_004 crossref_primary_10_1080_14737140_2023_2181795 crossref_primary_10_22517_25395203_25098 crossref_primary_10_1021_acsomega_1c00225 crossref_primary_10_3389_fonc_2021_742093 crossref_primary_10_1007_s12094_025_03845_w crossref_primary_10_1016_j_euros_2022_07_013 crossref_primary_10_1016_j_prnil_2023_04_001 crossref_primary_10_3390_ijtm2040047 crossref_primary_10_1016_S0140_6736_20_31952_8 crossref_primary_10_1038_s41391_022_00619_1 crossref_primary_10_1016_j_euros_2023_05_009 crossref_primary_10_1016_j_semradonc_2023_03_001 crossref_primary_10_1016_S0140_6736_20_31553_1 crossref_primary_10_4103_ijc_ijc_1145_21 crossref_primary_10_1016_j_fmre_2023_02_029 crossref_primary_10_1016_j_radonc_2022_08_001 crossref_primary_10_3389_fsurg_2021_691473 crossref_primary_10_1016_j_adro_2021_100753 crossref_primary_10_1016_j_cca_2020_11_027 crossref_primary_10_1038_s41391_023_00712_z crossref_primary_10_1016_j_ctrv_2023_102626 crossref_primary_10_1007_s00259_023_06438_3 crossref_primary_10_1111_bju_16445 crossref_primary_10_1002_pros_24806 crossref_primary_10_1007_s00761_021_00942_7 crossref_primary_10_1016_j_euo_2021_04_011 crossref_primary_10_1016_j_canrad_2021_10_009 crossref_primary_10_1007_s11912_023_01374_9 crossref_primary_10_1016_j_fjurol_2024_102710 crossref_primary_10_1016_j_euo_2021_04_008 crossref_primary_10_1186_s40001_023_01140_4 crossref_primary_10_1016_j_purol_2020_12_003 crossref_primary_10_1002_pros_24373 crossref_primary_10_1002_pros_24377 crossref_primary_10_1007_s00345_023_04419_7 crossref_primary_10_1016_j_ctro_2022_04_010 crossref_primary_10_1007_s00259_021_05557_z crossref_primary_10_3390_cancers15225334 crossref_primary_10_3389_fonc_2021_676716 crossref_primary_10_1016_j_apmt_2022_101584 crossref_primary_10_3390_medicina59061144 crossref_primary_10_1002_pros_24301 crossref_primary_10_1016_j_eururo_2024_09_011 crossref_primary_10_3390_cancers16132465 crossref_primary_10_1002_bco2_413 crossref_primary_10_1016_j_eururo_2024_04_034 crossref_primary_10_1016_j_eururo_2024_09_017 crossref_primary_10_1093_ajcp_aqae049 crossref_primary_10_3390_cancers13051133 crossref_primary_10_1038_s41571_020_00443_3 crossref_primary_10_1016_j_esmoop_2022_100432 crossref_primary_10_1002_pros_24653 crossref_primary_10_1038_s41391_024_00876_2 crossref_primary_10_1007_s10147_025_02714_4 crossref_primary_10_1111_ajco_14144 crossref_primary_10_20960_revcancer_00059 crossref_primary_10_1016_j_brachy_2022_12_002 crossref_primary_10_1136_bmjopen_2023_075846 crossref_primary_10_7759_cureus_68945 crossref_primary_10_3390_jcm13020446 crossref_primary_10_1111_bju_15422 crossref_primary_10_1007_s12094_022_03005_4 crossref_primary_10_1016_j_ijrobp_2020_12_022 crossref_primary_10_1016_j_ijrobp_2020_12_020 crossref_primary_10_3390_life13071610 crossref_primary_10_3390_life14070870 crossref_primary_10_1016_S0140_6736_21_00268_3 crossref_primary_10_25259_NMJI_127_21 crossref_primary_10_1002_pros_24445 crossref_primary_10_1007_s11864_023_01162_4 crossref_primary_10_1016_j_urolonc_2021_02_012 crossref_primary_10_1016_j_eururo_2024_04_010 crossref_primary_10_1016_S0140_6736_21_00273_7 crossref_primary_10_7759_cureus_27678 crossref_primary_10_3389_fonc_2024_1379306 crossref_primary_10_1111_bju_15550 crossref_primary_10_1016_j_prnil_2024_03_001 crossref_primary_10_1016_j_tipsro_2024_100287 crossref_primary_10_1016_j_eururo_2022_01_042 crossref_primary_10_1007_s00066_021_01882_2 crossref_primary_10_4103_iju_iju_103_23 crossref_primary_10_1016_j_fpurol_2024_07_205 crossref_primary_10_1016_j_canrad_2021_11_017 crossref_primary_10_1002_pros_24452 crossref_primary_10_23736_S2724_6051_21_04539_0 crossref_primary_10_1016_j_urolonc_2021_02_002 crossref_primary_10_1159_000513258 crossref_primary_10_1371_journal_pone_0282494 crossref_primary_10_1016_S1470_2045_20_30456_3 crossref_primary_10_1136_bmjebm_2020_111592 crossref_primary_10_1186_s12885_023_11278_3 crossref_primary_10_1007_s12094_021_02665_y crossref_primary_10_1371_journal_pone_0256778 crossref_primary_10_1038_s41585_020_00392_7 crossref_primary_10_3390_cancers13133243 crossref_primary_10_1016_j_prro_2023_01_002 crossref_primary_10_1016_j_euo_2024_06_008 crossref_primary_10_17650_1726_9776_2023_19_4_139_147 crossref_primary_10_1016_j_adro_2022_101143 crossref_primary_10_1016_j_eururo_2022_11_002 |
| Cites_doi | 10.1016/j.ejca.2011.08.013 10.1056/NEJMoa1606220 10.1016/S0140-6736(20)31952-8 10.1016/S0140-6736(20)31553-1 10.1016/S0360-3016(01)01579-6 10.1016/j.juro.2006.10.097 10.1016/j.eururo.2019.07.001 10.1016/S1470-2045(20)30456-3 10.1200/JCO.2007.13.9881 10.1016/j.ijrobp.2010.04.039 10.1016/j.eururo.2019.05.011 10.1016/j.ijrobp.2010.09.027 10.1016/S0140-6736(05)67101-2 10.1016/j.ijrobp.2004.08.047 10.1016/j.eururo.2016.03.010 10.1016/j.juro.2008.11.032 10.1056/NEJMoa1607529 10.1016/j.eururo.2014.03.011 10.1016/j.ijrobp.2011.09.007 10.1016/S0140-6736(12)61253-7 10.1016/S1470-2045(10)70223-0 10.1016/j.eururo.2013.01.027 10.1016/S1470-2045(19)30486-3 10.1016/j.ijrobp.2019.08.029 10.1001/jama.292.7.821 10.1016/j.eururo.2015.04.003 10.1016/j.eururo.2009.05.041 10.1200/JCO.2008.18.9563 10.1016/S1470-2045(16)00111-X 10.1200/JCO.2017.73.9987 10.1016/j.ijrobp.2018.08.052 10.1200/JCO.2006.10.4505 |
| ContentType | Journal Article |
| Copyright | 2020 Elsevier Ltd Elsevier Ltd Copyright © 2020 Elsevier Ltd. All rights reserved. 2020. Elsevier Ltd Attribution - NonCommercial |
| Copyright_xml | – notice: 2020 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2020 Elsevier Ltd. All rights reserved. – notice: 2020. Elsevier Ltd – notice: Attribution - NonCommercial |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7TO 7X7 7XB 88E 8AO 8C1 8C2 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 1XC VOOES |
| DOI | 10.1016/S1470-2045(20)30454-X |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database (Proquest) Oncogenes and Growth Factors Abstracts Health & Medical Collection (Proquest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Proquest Public Health Database Lancet Titles Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central ProQuest Central UK/Ireland ProQuest Central ProQuest One Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Oncogenes and Growth Factors Abstracts MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-5488 |
| EndPage | 1352 |
| ExternalDocumentID | oai_HAL_hal_03491498v1 33002438 10_1016_S1470_2045_20_30454_X S147020452030454X 1_s2_0_S147020452030454X |
| Genre | Clinical Trial, Phase III Multicenter Study Equivalence Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | France |
| GeographicLocations_xml | – name: France |
| GrantInformation | French Health Ministry and Ipsen. |
| GroupedDBID | --- --K --M -RU .1- .55 .FO 0R~ 123 1B1 1P~ 1~5 29L 4.4 457 4CK 4G. 53G 5VS 6PF 7-5 71M 7RV 7X7 88E 8AO 8C1 8C2 8FI 8FJ AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABMAC ABMZM ABUWG ABWVN ACGFS ACIEU ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AEIPS AEKER AENEX AEUPX AEVXI AFKRA AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA HMCUK HVGLF HZ~ IHE J1W KOM M1P M41 MO0 N9A NAPCQ O-L O9- OC~ OO- OZT P-8 P-9 P2P PCD PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO R2- ROL RPZ SDG SEL SES SPCBC SSH SSZ T5K TLN UKHRP UV1 WOW X7M XBR Z5R 3V. AACTN AFCTW AFKWA AJOXV ALIPV AMFUW RIG SDF ABLVK ABYKQ AHPSJ AJBFU ZA5 AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7TO 7XB 8FK H94 K9. PKEHL PQEST PQUKI PRINS 7X8 ACLOT ~HD 1XC VOOES |
| ID | FETCH-LOGICAL-c583t-c51c178e72b6d3557ae5534079c9df5c007b430e5aadb5ff78a84e0b9ddf52713 |
| IEDL.DBID | 7X7 |
| ISSN | 1470-2045 1474-5488 |
| IngestDate | Fri Sep 12 12:45:45 EDT 2025 Sun Sep 28 08:53:41 EDT 2025 Wed Aug 13 11:17:54 EDT 2025 Wed Feb 19 02:27:50 EST 2025 Thu Apr 24 22:53:22 EDT 2025 Tue Jul 01 01:53:24 EDT 2025 Fri Feb 23 02:37:08 EST 2024 Sun Feb 23 10:18:52 EST 2025 Tue Aug 26 16:33:28 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Language | English |
| License | Copyright © 2020 Elsevier Ltd. All rights reserved. Attribution - NonCommercial: http://creativecommons.org/licenses/by-nc |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c583t-c51c178e72b6d3557ae5534079c9df5c007b430e5aadb5ff78a84e0b9ddf52713 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0001-6019-7309 0000-0003-2094-1708 0000-0001-6556-063X 0000-0002-5255-6356 |
| OpenAccessLink | https://hal.science/hal-03491498 |
| PMID | 33002438 |
| PQID | 2446966069 |
| PQPubID | 46089 |
| PageCount | 12 |
| ParticipantIDs | hal_primary_oai_HAL_hal_03491498v1 proquest_miscellaneous_2448412636 proquest_journals_2446966069 pubmed_primary_33002438 crossref_citationtrail_10_1016_S1470_2045_20_30454_X crossref_primary_10_1016_S1470_2045_20_30454_X elsevier_sciencedirect_doi_10_1016_S1470_2045_20_30454_X elsevier_clinicalkeyesjournals_1_s2_0_S147020452030454X elsevier_clinicalkey_doi_10_1016_S1470_2045_20_30454_X |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-10-01 |
| PublicationDateYYYYMMDD | 2020-10-01 |
| PublicationDate_xml | – month: 10 year: 2020 text: 2020-10-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | The lancet oncology |
| PublicationTitleAlternate | Lancet Oncol |
| PublicationYear | 2020 |
| Publisher | Elsevier Ltd Elsevier Limited Elsevier |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited – name: Elsevier |
| References | Pollack AK, Karrison TG, Balogh Jr AG, et al. Short term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiotherapy: the NRG Oncology/RTOG 0534 SPPORT trial. ASTRO 60th Annual Meeting; San Antonia, TX, USA; Oct 21–24, 2018 (abstr LBA5). Cookson, Aus, Burnett (bib12) 2007; 177 Ost, Cozzarini, De Meerleer (bib21) 2012; 83 Ohri, Dicker, Trabulsi, Showalter (bib28) 2012; 48 Ost, De Troyer, Fonteyne, Oosterlinck, De Meerleer (bib31) 2011; 80 Vale, Fisher, Kneebone (bib14) 2020 Hackman, Taari, Tammela (bib27) 2019; 76 Wiegel, Bottke, Steiner (bib16) 2009; 27 Sineshaw, Gray, Efstathiou, Jemal (bib7) 2015; 68 Roach, Bae, Speight (bib19) 2008; 26 Pilepich, Winter, John (bib11) 2001; 50 Hamdy, Donovan, Lane (bib1) 2016; 375 Suardi, Gallina, Lista (bib6) 2014; 65 Cozzarini, Fiorino, Da Pozzo (bib29) 2012; 82 Parker, Clarke, Cook (bib8) 2020 Carrie, Magné, Burban-Provost (bib23) 2019; 20 Carrie, Hasbini, de Laroche (bib22) 2016; 17 Moinpour, Hayden, Unger (bib26) 2008; 26 Xie, Regan, Buyse (bib33) 2017; 35 D'Amico, Manola, Loffredo, Renshaw, DellaCroce, Kantoff (bib10) 2004; 292 Bolla, Van Tienhoven, Warde (bib18) 2010; 11 Thompson, Tangen, Paradelo (bib3) 2009; 181 Bolla, van Poppel, Tombal (bib4) 2012; 380 Marchal, Bensadoun, Haslé, Lapeyre, Carrere, Gérard (bib30) 2003; 7 Kneebone, Fraser-Browne, Duchesne (bib9) 2020; 21 Spratt DE, Dess RT, Efstathiou JA, et al. Two years of anti-androgen treatment increases other-cause mortality in men receiving early salvage radiotherapy: a secondary analysis of the NRG Oncology/RTOG 9601 randomized phase 3 trial. ASTRO 2019; Chicago, IL, USA; Sept 156–18, 2019 (abstr LBA1). Shipley, Seiferheld, Lukka (bib13) 2017; 376 Bolla, van Poppel, Collette (bib15) 2005; 366 Ost, Fonteyne, Villeirs, Lumen, Oosterlinck, De Meerleer (bib17) 2009; 56 van Stam, Aaronson, Pos (bib5) 2016; 70 Pilepich, Winter, Lawton (bib20) 2005; 61 Wiegel, Bartkowiak, Bottke (bib2) 2014; 66 Akthar, Liao, Eggener, Liauw (bib32) 2019; 76 Cozzarini (10.1016/S1470-2045(20)30454-X_bib29) 2012; 82 Hackman (10.1016/S1470-2045(20)30454-X_bib27) 2019; 76 van Stam (10.1016/S1470-2045(20)30454-X_bib5) 2016; 70 Moinpour (10.1016/S1470-2045(20)30454-X_bib26) 2008; 26 Sineshaw (10.1016/S1470-2045(20)30454-X_bib7) 2015; 68 Bolla (10.1016/S1470-2045(20)30454-X_bib4) 2012; 380 Ost (10.1016/S1470-2045(20)30454-X_bib31) 2011; 80 Pilepich (10.1016/S1470-2045(20)30454-X_bib11) 2001; 50 Wiegel (10.1016/S1470-2045(20)30454-X_bib2) 2014; 66 Suardi (10.1016/S1470-2045(20)30454-X_bib6) 2014; 65 Carrie (10.1016/S1470-2045(20)30454-X_bib23) 2019; 20 Ost (10.1016/S1470-2045(20)30454-X_bib21) 2012; 83 Bolla (10.1016/S1470-2045(20)30454-X_bib18) 2010; 11 10.1016/S1470-2045(20)30454-X_bib24 Roach (10.1016/S1470-2045(20)30454-X_bib19) 2008; 26 10.1016/S1470-2045(20)30454-X_bib25 Akthar (10.1016/S1470-2045(20)30454-X_bib32) 2019; 76 Thompson (10.1016/S1470-2045(20)30454-X_bib3) 2009; 181 Cookson (10.1016/S1470-2045(20)30454-X_bib12) 2007; 177 Carrie (10.1016/S1470-2045(20)30454-X_bib22) 2016; 17 Hamdy (10.1016/S1470-2045(20)30454-X_bib1) 2016; 375 Shipley (10.1016/S1470-2045(20)30454-X_bib13) 2017; 376 Xie (10.1016/S1470-2045(20)30454-X_bib33) 2017; 35 Wiegel (10.1016/S1470-2045(20)30454-X_bib16) 2009; 27 Bolla (10.1016/S1470-2045(20)30454-X_bib15) 2005; 366 Marchal (10.1016/S1470-2045(20)30454-X_bib30) 2003; 7 Parker (10.1016/S1470-2045(20)30454-X_bib8) 2020 Kneebone (10.1016/S1470-2045(20)30454-X_bib9) 2020; 21 Pilepich (10.1016/S1470-2045(20)30454-X_bib20) 2005; 61 Ost (10.1016/S1470-2045(20)30454-X_bib17) 2009; 56 D'Amico (10.1016/S1470-2045(20)30454-X_bib10) 2004; 292 Vale (10.1016/S1470-2045(20)30454-X_bib14) 2020 Ohri (10.1016/S1470-2045(20)30454-X_bib28) 2012; 48 33279305 - Eur Urol. 2021 Apr;79(4):555-556 33610298 - Int J Radiat Oncol Biol Phys. 2021 Mar 15;109(4):839-843 33067593 - Nat Rev Clin Oncol. 2021 Jan;18(1):5 33002430 - Lancet. 2020 Oct 31;396(10260):1374-1375 33478266 - J Urol. 2021 Apr;205(4):1225-1227 33077912 - Nat Rev Urol. 2020 Dec;17(12):657 |
| References_xml | – volume: 181 start-page: 956 year: 2009 end-page: 962 ident: bib3 article-title: Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial publication-title: J Urol – volume: 76 start-page: 686 year: 2019 end-page: 692 ident: bib32 article-title: Patient-reported outcomes and late toxicity after postprostatectomy intensity-modulated radiation therapy publication-title: Eur Urol – volume: 70 start-page: 751 year: 2016 end-page: 757 ident: bib5 article-title: The effect of salvage radiotherapy and its timing on the health-related quality of life of prostate cancer patients publication-title: Eur Urol – volume: 65 start-page: 546 year: 2014 end-page: 551 ident: bib6 article-title: Impact of adjuvant radiation therapy on urinary continence recovery after radical prostatectomy publication-title: Eur Urol – volume: 48 start-page: 837 year: 2012 end-page: 844 ident: bib28 article-title: Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling publication-title: Eur J Cancer – volume: 17 start-page: 747 year: 2016 end-page: 756 ident: bib22 article-title: Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial publication-title: Lancet Oncol – volume: 82 start-page: 191 year: 2012 end-page: 199 ident: bib29 article-title: Clinical factors predicting late severe urinary toxicity after postoperative radiotherapy for prostate carcinoma: a single-institute analysis of 742 patients publication-title: Int J Radiat Oncol Biol Phys – reference: Spratt DE, Dess RT, Efstathiou JA, et al. Two years of anti-androgen treatment increases other-cause mortality in men receiving early salvage radiotherapy: a secondary analysis of the NRG Oncology/RTOG 9601 randomized phase 3 trial. ASTRO 2019; Chicago, IL, USA; Sept 156–18, 2019 (abstr LBA1). – volume: 21 start-page: 1331 year: 2020 end-page: 1340 ident: bib9 article-title: Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial publication-title: Lancet Oncol – volume: 68 start-page: 768 year: 2015 end-page: 774 ident: bib7 article-title: Declining use of radiotherapy for adverse features after radical prostatectomy: results from the National Cancer Data Base publication-title: Eur Urol – volume: 83 start-page: 960 year: 2012 end-page: 965 ident: bib21 article-title: High-dose adjuvant radiotherapy after radical prostatectomy with or without androgen deprivation therapy publication-title: Int J Radiat Oncol Biol Phys – volume: 56 start-page: 669 year: 2009 end-page: 675 ident: bib17 article-title: Adjuvant high-dose intensity-modulated radiotherapy after radical prostatectomy for prostate cancer: clinical results in 104 patients publication-title: Eur Urol – volume: 35 start-page: 3097 year: 2017 end-page: 3104 ident: bib33 article-title: Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer publication-title: J Clin Oncol – volume: 76 start-page: 586 year: 2019 end-page: 595 ident: bib27 article-title: Randomised trial of adjuvant radiotherapy following radical prostatectomy versus radical prostatectomy alone in prostate cancer patients with positive margins or extracapsular axtension publication-title: Eur Urol – volume: 375 start-page: 1415 year: 2016 end-page: 1424 ident: bib1 article-title: 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer publication-title: N Engl J Med – volume: 61 start-page: 1285 year: 2005 end-page: 1290 ident: bib20 article-title: Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase 3 RTOG 85-31 publication-title: Int J Radiat Oncol Biol Phys – volume: 66 start-page: 243 year: 2014 end-page: 250 ident: bib2 article-title: Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial publication-title: Eur Urol – volume: 380 start-page: 2018 year: 2012 end-page: 2027 ident: bib4 article-title: Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) publication-title: Lancet – volume: 376 start-page: 417 year: 2017 end-page: 428 ident: bib13 article-title: Radiation with or without antiandrogen therapy in recurrent prostate cancer publication-title: N Engl J Med – volume: 26 start-page: 585 year: 2008 end-page: 591 ident: bib19 article-title: Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610 publication-title: J Clin Oncol – volume: 80 start-page: 1316 year: 2011 end-page: 1322 ident: bib31 article-title: A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancer publication-title: Int J Radiat Oncol Biol Phys – year: 2020 ident: bib8 article-title: Timing of radiotherapy after radical prostatectomy (RADICALS RT): a randomised, controlled phase 3 trial publication-title: Lancet – year: 2020 ident: bib14 article-title: Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data publication-title: Lancet – volume: 366 start-page: 572 year: 2005 end-page: 578 ident: bib15 article-title: Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911) publication-title: Lancet – volume: 50 start-page: 1243 year: 2001 end-page: 1252 ident: bib11 article-title: Phase 3 radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate publication-title: Int J Radiat Oncol Biol Phys – volume: 177 start-page: 540 year: 2007 end-page: 545 ident: bib12 article-title: Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes publication-title: J Urol – reference: Pollack AK, Karrison TG, Balogh Jr AG, et al. Short term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiotherapy: the NRG Oncology/RTOG 0534 SPPORT trial. ASTRO 60th Annual Meeting; San Antonia, TX, USA; Oct 21–24, 2018 (abstr LBA5). – volume: 27 start-page: 2924 year: 2009 end-page: 2930 ident: bib16 article-title: Phase 3 postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95 publication-title: J Clin Oncol – volume: 7 start-page: 44s year: 2003 end-page: 48s ident: bib30 article-title: Intensity modulated radiotherapy (IMRT) in France: the boost of the national funding for the new expensive innovative technologies (STIC 2001 and 2002) publication-title: Cancer Radiother – volume: 292 start-page: 821 year: 2004 end-page: 827 ident: bib10 article-title: 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial publication-title: JAMA – volume: 26 start-page: 112 year: 2008 end-page: 120 ident: bib26 article-title: Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy publication-title: J Clin Oncol – volume: 11 start-page: 1066 year: 2010 end-page: 1073 ident: bib18 article-title: External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study publication-title: Lancet Oncol – volume: 20 start-page: 1740 year: 2019 end-page: 1749 ident: bib23 article-title: Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial publication-title: Lancet Oncol – volume: 48 start-page: 837 year: 2012 ident: 10.1016/S1470-2045(20)30454-X_bib28 article-title: Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling publication-title: Eur J Cancer doi: 10.1016/j.ejca.2011.08.013 – volume: 375 start-page: 1415 year: 2016 ident: 10.1016/S1470-2045(20)30454-X_bib1 article-title: 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1606220 – year: 2020 ident: 10.1016/S1470-2045(20)30454-X_bib14 article-title: Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data publication-title: Lancet doi: 10.1016/S0140-6736(20)31952-8 – year: 2020 ident: 10.1016/S1470-2045(20)30454-X_bib8 article-title: Timing of radiotherapy after radical prostatectomy (RADICALS RT): a randomised, controlled phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(20)31553-1 – volume: 50 start-page: 1243 year: 2001 ident: 10.1016/S1470-2045(20)30454-X_bib11 article-title: Phase 3 radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/S0360-3016(01)01579-6 – volume: 177 start-page: 540 year: 2007 ident: 10.1016/S1470-2045(20)30454-X_bib12 publication-title: J Urol doi: 10.1016/j.juro.2006.10.097 – volume: 76 start-page: 586 year: 2019 ident: 10.1016/S1470-2045(20)30454-X_bib27 article-title: Randomised trial of adjuvant radiotherapy following radical prostatectomy versus radical prostatectomy alone in prostate cancer patients with positive margins or extracapsular axtension publication-title: Eur Urol doi: 10.1016/j.eururo.2019.07.001 – volume: 21 start-page: 1331 year: 2020 ident: 10.1016/S1470-2045(20)30454-X_bib9 article-title: Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30456-3 – volume: 7 start-page: 44s issue: suppl 1 year: 2003 ident: 10.1016/S1470-2045(20)30454-X_bib30 article-title: Intensity modulated radiotherapy (IMRT) in France: the boost of the national funding for the new expensive innovative technologies (STIC 2001 and 2002) publication-title: Cancer Radiother – volume: 26 start-page: 585 year: 2008 ident: 10.1016/S1470-2045(20)30454-X_bib19 article-title: Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610 publication-title: J Clin Oncol doi: 10.1200/JCO.2007.13.9881 – volume: 80 start-page: 1316 year: 2011 ident: 10.1016/S1470-2045(20)30454-X_bib31 article-title: A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancer publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2010.04.039 – volume: 76 start-page: 686 year: 2019 ident: 10.1016/S1470-2045(20)30454-X_bib32 article-title: Patient-reported outcomes and late toxicity after postprostatectomy intensity-modulated radiation therapy publication-title: Eur Urol doi: 10.1016/j.eururo.2019.05.011 – volume: 82 start-page: 191 year: 2012 ident: 10.1016/S1470-2045(20)30454-X_bib29 article-title: Clinical factors predicting late severe urinary toxicity after postoperative radiotherapy for prostate carcinoma: a single-institute analysis of 742 patients publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2010.09.027 – volume: 366 start-page: 572 year: 2005 ident: 10.1016/S1470-2045(20)30454-X_bib15 article-title: Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911) publication-title: Lancet doi: 10.1016/S0140-6736(05)67101-2 – volume: 61 start-page: 1285 year: 2005 ident: 10.1016/S1470-2045(20)30454-X_bib20 article-title: Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase 3 RTOG 85-31 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2004.08.047 – volume: 70 start-page: 751 year: 2016 ident: 10.1016/S1470-2045(20)30454-X_bib5 article-title: The effect of salvage radiotherapy and its timing on the health-related quality of life of prostate cancer patients publication-title: Eur Urol doi: 10.1016/j.eururo.2016.03.010 – volume: 181 start-page: 956 year: 2009 ident: 10.1016/S1470-2045(20)30454-X_bib3 article-title: Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial publication-title: J Urol doi: 10.1016/j.juro.2008.11.032 – volume: 376 start-page: 417 year: 2017 ident: 10.1016/S1470-2045(20)30454-X_bib13 article-title: Radiation with or without antiandrogen therapy in recurrent prostate cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1607529 – volume: 66 start-page: 243 year: 2014 ident: 10.1016/S1470-2045(20)30454-X_bib2 article-title: Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial publication-title: Eur Urol doi: 10.1016/j.eururo.2014.03.011 – volume: 83 start-page: 960 year: 2012 ident: 10.1016/S1470-2045(20)30454-X_bib21 article-title: High-dose adjuvant radiotherapy after radical prostatectomy with or without androgen deprivation therapy publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2011.09.007 – volume: 380 start-page: 2018 year: 2012 ident: 10.1016/S1470-2045(20)30454-X_bib4 article-title: Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) publication-title: Lancet doi: 10.1016/S0140-6736(12)61253-7 – volume: 11 start-page: 1066 year: 2010 ident: 10.1016/S1470-2045(20)30454-X_bib18 article-title: External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(10)70223-0 – volume: 65 start-page: 546 year: 2014 ident: 10.1016/S1470-2045(20)30454-X_bib6 article-title: Impact of adjuvant radiation therapy on urinary continence recovery after radical prostatectomy publication-title: Eur Urol doi: 10.1016/j.eururo.2013.01.027 – volume: 20 start-page: 1740 year: 2019 ident: 10.1016/S1470-2045(20)30454-X_bib23 article-title: Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(19)30486-3 – ident: 10.1016/S1470-2045(20)30454-X_bib25 doi: 10.1016/j.ijrobp.2019.08.029 – volume: 292 start-page: 821 year: 2004 ident: 10.1016/S1470-2045(20)30454-X_bib10 article-title: 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial publication-title: JAMA doi: 10.1001/jama.292.7.821 – volume: 68 start-page: 768 year: 2015 ident: 10.1016/S1470-2045(20)30454-X_bib7 article-title: Declining use of radiotherapy for adverse features after radical prostatectomy: results from the National Cancer Data Base publication-title: Eur Urol doi: 10.1016/j.eururo.2015.04.003 – volume: 56 start-page: 669 year: 2009 ident: 10.1016/S1470-2045(20)30454-X_bib17 article-title: Adjuvant high-dose intensity-modulated radiotherapy after radical prostatectomy for prostate cancer: clinical results in 104 patients publication-title: Eur Urol doi: 10.1016/j.eururo.2009.05.041 – volume: 27 start-page: 2924 year: 2009 ident: 10.1016/S1470-2045(20)30454-X_bib16 article-title: Phase 3 postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95 publication-title: J Clin Oncol doi: 10.1200/JCO.2008.18.9563 – volume: 17 start-page: 747 year: 2016 ident: 10.1016/S1470-2045(20)30454-X_bib22 article-title: Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)00111-X – volume: 35 start-page: 3097 year: 2017 ident: 10.1016/S1470-2045(20)30454-X_bib33 article-title: Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2017.73.9987 – ident: 10.1016/S1470-2045(20)30454-X_bib24 doi: 10.1016/j.ijrobp.2018.08.052 – volume: 26 start-page: 112 year: 2008 ident: 10.1016/S1470-2045(20)30454-X_bib26 article-title: Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy publication-title: J Clin Oncol doi: 10.1200/JCO.2006.10.4505 – reference: 33279305 - Eur Urol. 2021 Apr;79(4):555-556 – reference: 33478266 - J Urol. 2021 Apr;205(4):1225-1227 – reference: 33077912 - Nat Rev Urol. 2020 Dec;17(12):657 – reference: 33067593 - Nat Rev Clin Oncol. 2021 Jan;18(1):5 – reference: 33002430 - Lancet. 2020 Oct 31;396(10260):1374-1375 – reference: 33610298 - Int J Radiat Oncol Biol Phys. 2021 Mar 15;109(4):839-843 |
| SSID | ssj0017105 |
| Score | 2.6858943 |
| Snippet | Adjuvant radiotherapy reduces the risk of biochemical progression in prostate cancer patients after radical prostatectomy. We aimed to compare adjuvant versus... SummaryBackgroundAdjuvant radiotherapy reduces the risk of biochemical progression in prostate cancer patients after radical prostatectomy. We aimed to compare... Summary Background Adjuvant radiotherapy reduces the risk of biochemical progression in prostate cancer patients after radical prostatectomy. We aimed to... Background: Adjuvant radiotherapy reduces the risk of biochemical progression in prostate cancer patients after radical prostatectomy. We aimed to compare... |
| SourceID | hal proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1341 |
| SubjectTerms | Activities of daily living Adenocarcinoma Adenocarcinoma - drug therapy Adenocarcinoma - pathology Adenocarcinoma - radiotherapy Adenocarcinoma - surgery Aged Androgen Antagonists - administration & dosage Androgens Cancer surgery Disease Progression Dissection Erectile dysfunction France Hematology, Oncology, and Palliative Medicine Humans Life Sciences Lymph nodes Lymphatic system Male Male Urogenital Diseases - epidemiology Male Urogenital Diseases - etiology Medical Overuse - prevention & control Metastasis Middle Aged Oncology Pathology Patients Prostate cancer Prostatectomy Prostatic Neoplasms - drug therapy Prostatic Neoplasms - pathology Prostatic Neoplasms - radiotherapy Prostatic Neoplasms - surgery Questionnaires Radiation therapy Radiotherapy, Adjuvant - adverse effects Salvage Therapy - adverse effects Survival Survival Analysis Toxicity Treatment Outcome Urological surgery |
| Title | Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S147020452030454X https://www.clinicalkey.es/playcontent/1-s2.0-S147020452030454X https://dx.doi.org/10.1016/S1470-2045(20)30454-X https://www.ncbi.nlm.nih.gov/pubmed/33002438 https://www.proquest.com/docview/2446966069 https://www.proquest.com/docview/2448412636 https://hal.science/hal-03491498 |
| Volume | 21 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier) customDbUrl: eissn: 1474-5488 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: GBLVA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Complete Freedom Collection [SCCMFC] customDbUrl: eissn: 1474-5488 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: ACRLP dateStart: 20000901 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1474-5488 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: AKRWK dateStart: 20000501 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1474-5488 dateEnd: 20250730 omitProxy: true ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: 7X7 dateStart: 20000901 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1474-5488 dateEnd: 20250730 omitProxy: true ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: BENPR dateStart: 20000901 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1474-5488 dateEnd: 20250730 omitProxy: true ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: 8C1 dateStart: 20000901 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1fb9MwELfYJiFeEP8JjMkgHjaJsDhx4pQXVKZ2FWITglXqm-XYjlrUpqVpJ-1r8om4c5xMSIzx4ofYFye6893v7PMdIW_TtFSlZixUYE1CtHhhryx5KMARM0bHBbN43_nsPBuN-edJOvEbbrUPq2x1olPUZqlxj_wYzFCGmSSz3sfVzxCrRuHpqi-hsUP2GEAVlGox6RwuJpoQRsZFFGLa9esbPMffu4eHcXSEx4U8nNxkm3amGCR5EwJ1lmj4gNz3EJL2G54_JHds9YjcPfOH5I_Jr775sQWAvKFrZWb-htUVxfiLbU0tZjSmtZpfgib5c8RqDv31FAB5iAqbKkxmAAJGMVzWV0Gj7eBZRRfQhfu41BnEWW0NXeElEoCvVKM0rakrQe5mgRFdr94sF1f08HRwMT4N-8MxZeLoA1UwrjLLBb7oHV1Nwb7ShLqyIk_IeDi4OBmFvnRDqNM82UDLNBO5FXGRGYA0Qtk0TcB57OmeKVMNyKTgSWRTpUyRlqXIVc5tVPQM9MbgOD8lu9Wyss8JBb2gsFBazHTCTVnkGqQr5axQLLKCm4DwlmlS-7zmWF5jLrsANuS1RF5DIx2v5SQg7zuyVZPY4zaCrJUI2d5aBT0rwfTcRij-Rmhrry1qyWQdy6ihRuLYnV9zoMw7Sg-IGqDzP5O-AaHt_gyTiI_6XyQ-w4xE4Bfnlywg-61My-5jrhdaQF533cB7PElSlV1u3ZgcOJIlWUCeNWuhmypJXJbL_MW_X_6S3Itx68LFRe6T3c16a18BvtsUB24RQ5ufsAOy92lw_vXbb4tjTKs |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3bbtMw1NqGBLwg7hQGGATSJhEWJ86lSAhVsK5j7V5opbwZx3bUojYtTTvUn-Jj-CLOcS4TEmO87CUP8Tl2onN8Lva5EPIqCDKZKcYcCdrEQY3ntLOMOxE4YlorL2UG850Hp2FvxD8nQbJFfta5MBhWWctEK6j1XOEZ-QGooRArSYbtD4vvDnaNwtvVuoVGyRYnZvMDXLbi_fEnoO9rz-seDj_2nKqrgKOC2F_BkykWxSby0lCDto2kCQIf_Jq2aussUKA0U-67JpBSp0GWRbGMuXHTtoZRD3w6mHebXAMQjrX6o6Rx8FhUhkwyHrkOlnk_zxg6-NK83PPcfbye5E5ykS7cHmNQ5kUWr9V83dvkVmWy0k7JY3fIlsnvkuuD6lL-HvnV0d_WYJCv6FLqSZXRtaEY77EuqMEKyrSQ0zOQXH9CLKYwXozBAXBQQVCJxROAoSmG51Zd12gNPMnpDIbw3JhaBTwpjKYLTFoBc5kq5N4ltS3P7SoA0Yyq1Xy2oXtHh8PRkdPpjiiL9t9RCXC5ns9wojd0MQZ9Tn1q25jcJ6MrIeoDspPPc_OIUJBDEhuzeUz5XGdprICbA85SyVwTcd0ivCaaUFUddWznMRVNwBzSWiCt4SEsrUXSIm8btEVZSOQyhLDmCFFnyYJcF6DqLkOM_oZoiko6FYKJwhNuiY3Inr0v54AZN5iVAVYaVv-z6Etg2ubPsGh5r9MX-A4rIIEfHp-xFtmteVo0H3O-sVvkRTMMtMebK5mb-drCxECR0A9b5GG5F5qlfN9W1Ywf_3vy5-RGbzjoi_7x6ckTctPDYxMbk7lLdlbLtXkKtuUqfWY3NCVfr1qC_Aar0Ida |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELe2IU28IL4pDDAIpE0iNE6cOEVCqGLrNvYhJFapb8axHbWoTUvTDvVf48_gL-LO-ZiQGONlL3mIfU6rO9_vzr4PQl5FUaYyzZinAE08RDyvk2XcE-CIGaODlFnMdz45jQ_6_NMgGqyRn3UuDIZV1jrRKWoz1XhG3gYYirGSZNxpZ1VYxOfd3ofZdw87SOFNa91OoxSRI7v6Ae5b8f5wF3j9Ogh6e2cfD7yqw4CnoyRcwJNpJhIrgjQ2gLxC2SgKwcfp6I7JIg0AmvLQt5FSJo2yTCQq4dZPOwZGA_DvYN11ckOEPMRwMjFonD0myvBJxoXvYcn3i-yh9pfm5Xbg7-BVJfcGl-Hi-hADNC-zfh0K9m6TW5X5SrulvN0haza_SzZPqgv6e-RX13xbgnG-oHNlRlV214pi7MeyoBarKdNCjc9Bi_05YzaG8WIIzoCHYEEVFlIA4aYYqlt1YKP15FFOJzCEZ8jUgfGosIbOMIEFTGeqUZLn1LU_d1-BGc2oXkwnK7q9v3fW3_e6vT5lYucdVTAvN9MJLvSGzoaA7TSkrqXJfdK_FqY-IBv5NLePCAWdpLBJW8B0yE2WJhokO-IsVcy3gpsW4TXTpK5qqmNrj7FsgueQ1xJ5DQ_peC0HLfK2IZuVRUWuIohriZB1xizoeAmwdxWh-BuhLSpNVUgmi0D6JTUSB-7unANl0lBWxlhpZP3PR1-C0Db_DAuYH3SPJb7DakjgkyfnrEW2apmWzY-52OQt8qIZBt7jLZbK7XTp5iTAkTiMW-RhuReaT4Whq7CZPP734s_JJugOeXx4evSE3AzwBMWFZ26RjcV8aZ-CmblIn7n9TMnX61YgvwFh3IuV |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Adjuvant+radiotherapy+versus+early+salvage+radiotherapy+plus+short-term+androgen+deprivation+therapy+in+men+with+localised+prostate+cancer+after+radical+prostatectomy+%28GETUG-AFU+17%29%3A+a+randomised%2C+phase+3+trial&rft.jtitle=The+lancet+oncology&rft.au=Sargos%2C+Paul%2C+MD&rft.au=Chabaud%2C+Sylvie%2C+MSc&rft.au=Latorzeff%2C+Igor%2C+MD&rft.au=Magn%C3%A9%2C+Nicolas%2C+Prof&rft.date=2020-10-01&rft.issn=1470-2045&rft.volume=21&rft.issue=10&rft.spage=1341&rft.epage=1352&rft_id=info:doi/10.1016%2FS1470-2045%2820%2930454-X&rft.externalDBID=ECK1-s2.0-S147020452030454X&rft.externalDocID=1_s2_0_S147020452030454X |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14702045%2FS1470204520X00106%2Fcov150h.gif |